From I Clinica Medica, University of Pisa, Italy.
Correspondence to Stefano Taddei, MD, I Clinica Medica, University of Pisa, Via Roma, 67, 56100 Pisa, Italy.
Methods and ResultsIn 14 healthy subjects (47.1±4.8 years;
blood pressure, 120.6±4.5/80.9±3.5 mm Hg) and 14 essential
hypertensive patients (47.3±5.1 years; blood pressure,
153.9±7.1/102.3±4.1 mm Hg), we studied forearm blood flow
(strain-gauge plethysmography) modifications induced by intrabrachial
acetylcholine (0.15, 0.45, 1.5, 4.5, and 15 µg · 100
mL-1 · min-1) or sodium nitroprusside
(1, 2, and 4 µg/100 mL forearm tissue per minute), an
endothelium-dependent and -independent vasodilator,
respectively, in basal conditions and during infusion of intrabrachial
vitamin C (2.4 mg/100 mL forearm tissue per minute). In hypertensive
patients but not in control subjects, vitamin C increased
(P<0.01) the impaired vasodilation to acetylcholine,
whereas the response to sodium nitroprusside was unaffected. Moreover,
in another 14 hypertensive patients (47.1±5.2 years; blood pressure,
155.2±6.9/103.7±4.5 mm Hg), the facilitating effect of vitamin
C on vasodilation to acetylcholine was reversed by
NG-monomethyl-L-arginine
(100 µg/100 mL forearm tissue per minute), a nitric oxide synthase
inhibitor, suggesting that in essential hypertension
superoxide anions impair endothelium-dependent
vasodilation by nitric oxide breakdown. Finally, because in adjunctive
7 hypertensive patients (47.8±6.1 years; blood pressure,
155.3±6.8/103.5±4.3 mm Hg), indomethacin (50
µg/100 mL forearm tissue per minute), a
cyclooxygenase inhibitor, prevented the
potentiating effect of vitamin C on vasodilation to acetylcholine, it
is possible that in essential hypertension a main source of superoxide
anions could be the cyclooxygenase pathway.
ConclusionsIn essential hypertensive patients, impaired
endothelial vasodilation can be improved by the
antioxidant vitamin C, an effect that can be reversed by the nitric
oxide synthase inhibitor
NG-monomethyl-L-arginine.
These findings support the hypothesis that nitric oxide inactivation by
oxygen free radicals contributes to endothelial
dysfunction in essential hypertension.
Essential hypertension is characterized by impaired
endothelium-dependent vasodilation to specific
agonists10 11 12 13 14 15 16 17 18 because of the presence of an
alteration in the L-arginineNO
pathway13 14 18 19 and production of
cyclooxygenase-dependent
EDCFs.12 19 It is worth noting that in essential
hypertensive patients blockade of EDCF production by
cyclooxygenase inhibition can restore the
L-arginineNO pathway,19 suggesting
that the alteration in the NO system can at least partially be caused
by cyclooxygenase derivatives. However, the nature
of these EDCFs still remains unidentified in human hypertension.
Superoxide anions are the predominant products of univalent
reduction of oxygen and are mediators of vascular
injury.20 They can be produced from a variety of
sources, including oxidative enzymes such as xanthine oxidase or
cyclooxygenase.21 22 Under
physiological conditions, these oxygen free
radicals are potent chemical inactivators of
NO.23 24 25 26 It has been proposed that
endothelial dysfunction associated with hypertension
could be determined by augmented production of superoxide
anions, which could impair the ability of endothelium
to induce NO-mediated relaxations of underlying smooth muscle
cells.27 28 29 Moreover, oxygen free radicals
produce contractions of rat aorta that are augmented in the
spontaneously hypertensive rat and, interestingly, are reduced in the
presence of cyclooxygenase inhibitors
and PGH2/TXA2 receptor
antagonists but not in the presence of
TXA2 synthethase
inhibitors.30 31 Therefore, the EDCFs
do not necessarily have to be prostanoids, but superoxide anions can
also be classified as EDCFs.32 Finally, treatment
with the antioxidant SOD33 or the
inhibitor of xanthine oxidase oxypurinol lowers blood
pressure in the spontaneously hypertensive rat but not in
controls34 ; moreover, acutely induced
hypertension has been shown to induce superoxide generation, which can
be reversed by SOD administration in cats.35
Whether a similar alteration is operating in human essential
hypertension is still to be determined. Therefore, the aim of the
present study was to investigate the possibility that oxygen free
radicals could be responsible for the impairment in the
L-arginineNO system of patients with essential
hypertension. To address this issue, we used vitamin C, which is an
important antioxidant capable of scavenging oxygen-derived free
radicals36 and sparing other
endogenous antioxidants from
consumption.37 The possibility that oxygen free
radicals could originate from cyclooxygenase
activity was also evaluated.
Subjects, defined as normal according to the absence of familial
history of essential hypertension and blood pressure values <140 to
90 mm Hg, were characterized by a mean age of 46.4±5.1 years and
blood pressure values of 120.8±4.3/80.7±3.2 mm Hg. Essential
hypertensive patients were recruited from among the newly diagnosed
patients in our outpatient clinic if they reported the presence of
positive family history of essential hypertension and when supine
arterial blood pressure (after 10 minutes of rest) measured
by mercury sphygmomanometer three times at 1-week intervals for 1 month
was consistently found to be >140/90 mm Hg. Secondary
forms of hypertension were excluded by routine diagnostic
procedures. Mean age was 47.1±5.4 years, and blood pressure values
were 154.8±6.8/102.2±4.4 mm Hg. Because the patients were newly
diagnosed, they had never been treated, and the known history of
hypertension had lasted 2.4±0.6 years. The demographic and clinical
characteristics of the two groups are shown in the
Table
Experimental Procedure
Forearm volume was measured according to the water displacement method.
Drug infusion rates were normalized to 100 mL tissue by alteration of
the drug concentration in the solvent while the pump speed of infusion
was kept constant. Drugs were infused at systemically ineffective rates
through separate ports via three-way stopcocks.
Experimental Design
Effect of L-NMMA on Response to Acetylcholine in the Absence and
Presence of Vitamin C
Effect of Cyclooxygenase Inhibition on Response
to Acetylcholine in the Presence of Vitamin C
Drugs
Data Analysis
Effect of L-NMMA on Response to Acetylcholine in the Absence and
Presence of Vitamin C
Effect of Cyclooxygenase Inhibition on Response
to Acetylcholine in the Presence of Vitamin C
When the activities of indomethacin and vitamin C were
compared in normotensive control subjects, acetylcholine-dependent
vasodilation (from 3.6±0.4 to 21.8±2.9 mL/100 mL forearm tissue per
minute) was not significantly increased by intrabrachial infusion of
indomethacin (from 3.5±0.4 to 21.4±2.6 mL/100 mL
forearm tissue per minute, P=NS versus acetylcholine during
saline) or vitamin C (from 3.6±0.5 to 21.1±3.1 mL/100 mL forearm
tissue per minute, P=NS versus acetylcholine during saline)
or the simultaneous administration of
indomethacin and vitamin C (FBF, from 3.6±0.4 to
21.9±2.6 mL/100 mL forearm tissue per minute; P=NS versus
acetylcholine during saline) (Figure 4
This possibility is reinforced by the results of the L-NMMA
study. In agreement with previous evidence, although intrabrachial
administration of L-NMMA clearly inhibited the vasodilating effect
of acetylcholine in normotensive subjects, it was found to be
ineffective in essential hypertensive patients, indicating an
alteration in the NO system. However, when L-NMMA was retested in the
same patients simultaneously with vitamin C, we observed
that the NO-synthase inhibitor clearly antagonized the
response to acetylcholine, indicating that in the presence of
superoxide anion scavenging, the activity of the
L-arginineNO pathway is restored. A likely explanation of
these findings could be that in basal conditions the L-NMMA effect is
masked by the fact that superoxide anions destroy NO produced by
NO-synthase activity. However, when vitamin C scavenges oxygen free
radicals and therefore increases the ability of acetylcholine to
produce NO, it also unmasks the inhibitory activity of
L-NMMA.
Therefore, taken together, these findings indicate that oxygen free
radicals may be responsible for endothelial dysfunction
in essential hypertension, probably through NO breakdown.
As regards the origin of oxidative stress in human hypertension, it is
of interest that available data indicate the
cyclooxygenase pathway to be the main source of
oxygen free radicals. Thus, previous evidence has indicated that
cyclooxygenase-dependent mechanisms induce
endothelial dysfunction in essential
hypertension,12 19 because
indomethacin can increase the response to acetylcholine
in hypertensive patients but not in healthy control subjects. Moreover,
it has recently been demonstrated that
cyclooxygenase-derived EDCFs at least partially
impair endothelium-dependent vasodilation by
inactivating NO formation,19 suggesting that
these factors could include oxygen free radicals. This possibility
seems to be confirmed by the present study. Thus,
cyclooxygenase inhibition by
indomethacin caused a potentiating effect on the
response to acetylcholine of the same degree as that exerted by vitamin
C. Moreover, when the two compounds were coinfused, no further
potentiation of the vasodilating effect of acetylcholine was observed.
Therefore, because the potentiation of indomethacin is
similar to that exerted by vitamin C and no additive effect was
observed from the association of these compounds, oxygen free radical
production is probably the main
cyclooxygenase-dependent mechanism responsible for
endothelial dysfunction in essential hypertension.
However, to rule out the possibility that prostanoids
(TXA2 and
PGH2)5 6 7 8 may also be
produced in the same experimental conditions, studies with specific
PGH2/TXA2 receptor
antagonists or TXA2 synthethase
inhibitors are needed to elucidate this issue.
Unfortunately, at the present time, such compounds are not
available for human use.
To further address the mechanism through which superoxide anions can
inactivate NO, it is worth considering the recent
demonstration that intra-arterial CuZn SOD is devoid of any
effect on vasodilation to acetylcholine in the forearm of essential
hypertensive patients.43 Because the main
difference between vitamin C and CuZn SOD is the respective high and
low ability of these scavengers to penetrate into
endothelial cells,32 36 it is
likely that the major part of NO destruction occurs within the
endothelium. This possibility is in agreement with the
present finding of a lack of vitamin Cinduced improvement in the
vasodilating response to the NO donor sodium nitroprusside, whose
effect should be impaired by extra-endothelial oxygen
free radical production.
Finally, it is important to note that superoxide anions seem to
be operating mainly when endothelial cells are
stimulated by acetylcholine. Thus, intrabrachial vitamin C was
ineffective in modifying basal flow, suggesting that superoxide anions
are not tonically produced. This possibility is confirmed by the
finding that vitamin C did not change the basal vasoconstrictor effect
of L-NMMA. As previously demonstrated,12 33
L-NMMAinduced vasoconstriction is blunted in hypertensive patients
compared with control subjects, indicating that NO basal release in
human vasculature is defective in essential hypertensive
patients.13 18 19 44 This finding is confirmed in
the present study, because the response to intrabrachial L-NMMA was
reduced in essential hypertensive patients compared with control
subjects. However, vitamin C did not change the vasoconstrictor effect
of L-NMMA, suggesting that oxygen free radical production is
not the cause of impaired tonic NO-mediated regulation of basal
flow.
Assessment of the clinical relevance of the present results should
take into account the fact that superoxide anion production has
been found to cause endothelial dysfunction in
presence of several cardiovascular risk factors. Thus,
in noninsulin-dependent diabetic patients41 or
smokers ,42 intrabrachial administration of
vitamin C can increase the impaired
endothelium-dependent vasodilation to methacholine and
acetylcholine, respectively. Moreover, in patients with
coronary artery disease and
hypercholesterolemia, the association of
antioxidant and cholesterol-lowering therapy by probucol
and lovastatin, respectively, can induce greater
improvement in endothelium-dependent coronary
artery vasomotion to acetylcholine compared with
cholesterol-lowering therapy alone.45
This line of evidence clearly suggests that oxygen-derived free radical
production could be a common mechanism accounting for impaired
endothelium-dependent vasodilation associated with
cardiovascular risk factors. Because there is
increasing evidence that endothelial dysfunction
contributes to the development of atherosclerotic
disease,46 47 48 49 it can be hypothesized that
oxidative stress could be one of the most important pathogenetic
mechanisms. In line with this possibility, it has been demonstrated
that in patients with atherosclerotic coronary artery disease,
oral administration of vitamin C selectively reverses
endothelial vasomotor dysfunction of the brachial
artery.50 Finally, epidemiological studies
indicate an association between increased intake of antioxidant
vitamins and reduced risk of coronary
disease,51 52 53 whereas the Cambridge Heart
Antioxidant Study indicates that 1-year treatment with the antioxidant
vitamin E reduces the rate of nonfatal myocardial infarction in
patients with angiographically proven symptomatic
coronary
atherosclerosis.54
In conclusion, the present results indicate that in essential
hypertensive patients the antioxidant vitamin C improves
endothelium-dependent vasodilation by at least
partially restoring L-arginineNO pathway activity. This
finding supports the hypothesis that oxygen-derived free radicals,
possibly cyclooxygenase-derived superoxide anions,
could be responsible for endothelial dysfunction in
essential hypertension. Because the same mechanism is operating in
presence of several cardiovascular risk factors,
reversing endothelial dysfunction by antioxidant
therapy could be important in reducing the development of
cardiovascular disease. Therefore, the results of
ongoing studies such as the Heart Outcome Prevention Evaluation
study55 and the Oxford Heart Protection
Study,56 evaluating the long-term effect of oral
antioxidant vitamin supplementation on cardiovascular
morbidity and mortality, will be crucial to our understanding of the
effective clinical relevance of oxidative stress in human
cardiovascular disease.
Received November 24, 1997;
revision received January 7, 1998;
accepted January 30, 1998.
2.
Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide
release accounts for the biological activity of
endothelium-derived relaxing factor. Nature. 1987;327:524526.[Medline]
[Order article via Infotrieve]
3.
Palmer RMJ, Ashton DS, Moncada S. Vascular
endothelial cells synthesize nitric oxide from
L-arginine. Nature. 1988;333:664666.[Medline]
[Order article via Infotrieve]
4.
Rees DD, Palmer RMJ, Hodson HF, Moncada S. A specific
inhibitor of nitric oxide formation from
L-arginine attenuates endothelium-dependent
relaxation. Br J Pharmacol. 1989;96:418424.[Medline]
[Order article via Infotrieve]
5.
Vallance P, Coller J, Moncada S. Effects of
endothelium-derived nitric oxide on
peripheral arteriolar tone in man. Lancet. 1989;2:9971000.[Medline]
[Order article via Infotrieve]
6.
Lüscher TF, Vanhoutte PM.
Endothelium-dependent contractions to acetylcholine in
the aorta of spontaneously hypertensive rats. Hypertension. 1986;8:344348.
7.
Shirahase H, Fujiwara M, Usui H, Kurahashi K. A
possible role of thromboxane A2 in
endothelium in maintaining resting tone and producing
contractile response to acetylcholine and arachidonic
acid in canine cerebral artery. Blood Vessels. 1987;24:117119.[Medline]
[Order article via Infotrieve]
8.
Kato T, Iwama Y, Okumura K, Hashimoto H, Ito T, Satake
T. Prostaglandin H2 may be the
endothelium-derived contracting factor released by
acetylcholine in the aorta of the rat. Hypertension. 1990;15:475482.
9.
Katusic ZS, Vanhoutte PM. Superoxide anion is an
endothelium-derived contracting factor. Am J
Physiol. 1989;257:H33H37.
10.
Linder L, Kiowski W, Bühler FR, Lüscher TF.
Indirect evidence for the release of
endothelium-derived relaxing factor in the human
forearm circulation in vivo: blunted response in essential
hypertension. Circulation. 1990;81:17621767.
11.
Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal
endothelium dependent vascular relaxation in patients
with essential hypertension. N Engl J Med. 1990;323:2227.[Abstract]
12.
Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation
to acetylcholine in primary and secondary forms of human hypertension.
Hypertension. 1993;21:929933.
13.
Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of
endothelium-derived nitric oxide in the abnormal
endothelium-dependent vascular relaxation of patients
with essential hypertension. Circulation. 1993;87:14681474.
14.
Panza JA, Casino PR, Badar DM, Quyyumi AA. Effect of
increased availability of endothelium-derived nitric
oxide precursor on endothelium-dependent vascular
relaxation in normal subjects and in patients with essential
hypertension. Circulation. 1993;87:14751481.
15.
Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired
endothelium-dependent vasodilation in patients with
essential hypertension: evidence that the abnormality is not at the
muscarinic receptor level. J Am Coll Cardiol. 1994;23:16101616.[Abstract]
16.
Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A,
Basile Fasolo C, Sudano I, Salvetti A. Aging and
endothelial function in normotensive subjects and
essential hypertensive patients. Circulation. 1995;91:19811987.
17.
Panza JA, García CE, Kilcoyne CM, Quyyumi A,
Cannon RO III. Impaired endothelium-dependent
vasodilation in patients with essential hypertension: evidence that
nitric oxide abnormality is not localized to a single signal
transduction pathway. Circulation. 1995;91:17321738.
18.
Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E,
Salvetti A. Effect of insulin on acetylcholine-induced vasodilation in
normotensive subjects and patients with essential hypertension.
Circulation. 1995;92:29112918.
19.
Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A.
Cyclooxygenase inhibition restores nitric oxide
activity in essential hypertension. Hypertension.
1997;29(suppl 1, pt 2):274279.
20.
Kontos HA, Kontos MC. Role of products of univalent
reduction of oxygen in hypertensive vascular injury. In: Laragh JH,
Brenner, BM, eds. Hypertension: Pathophysiology, Diagnosis, and
Management. 2nd ed. New York, NY: Raven Press, Ltd; 1995:685696.
21.
Fridovich I. The biology of oxygen radicals.
Science. 1978;201:875880.
22.
Chance B, Sies H, Boveris A. Hydroperoxide
metabolism in mammalian organs. Physiol Rev. 1979;59:527605.
23.
Griffith TM, Edwards DH, Lewis MJ, Newby AC, Henderson
AH. The nature of endothelium-derived relaxant factor.
Nature. 1984;308:645647.[Medline]
[Order article via Infotrieve]
24.
Rubanyi GM, Vanhoutte PM. Superoxide anions and
hyperoxia inactivate endothelium-derived
relaxing factors. Am J Physiol. 1986;250:H822H827.
25.
Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion
plays a role in the breakdown of endothelium-derived
relaxing factor. Nature. 1986;320:454456.[Medline]
[Order article via Infotrieve]
26.
Mügge A, Elwell JH, Peterson TE, Harrison DG.
Release of intact endothelium-dependent relaxing factor
depends on endothelial superoxide dismutase activity.
Am J Physiol. 1991;260:C219C225.
27.
Sunman W, Hughes AD, Sever PS. Free-radical scavengers,
thiol-containing reagents and endothelium-dependent
relaxation in isolated rat and human resistance arteries. Clin
Sci. 1993;84:287295.[Medline]
[Order article via Infotrieve]
28.
Grunfeld S, Hamilton CA, Mesaros S, McClain SW,
Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed
nitric oxide production by the endothelium of
genetically hypertensive rats. Hypertension. 1995;26(pt
1):854857.
29.
Tschudi MR, Mesaros S, Lüscher TF, Malinski T.
Direct in situ measurement of nitric oxide in mesenteric resistance
arteries. Hypertension. 1996;27:3235.
30.
Auch-Schwelk W, Katusic ZS, Vanhoutte PM.
Thromboxane A2 receptor
antagonists inhibit endothelium-dependent
contractions. Hypertension. 1990;15:699703.
31.
Cosentino F, Sill JC, Katusic ZS. Role of superoxide
anions in the mediation of endothelium-3 dependent
contraction. Hypertension. 1994;23:229235.
32.
Katusic ZS, Shepherd JT.
Endothelium-derived vasoactive factors, II:
endothelium-dependent contraction.
Hypertension. 1991;18(suppl III):III-86III-92.
33.
Omar BA, Flores SC, McCord JM. Superoxide dismutase:
pharmacological developments and applications. Adv
Pharmacol. 1992;23:109161.
34.
Nakazono K, Watanabe N, Matsuno K, Sasak J, Sato T.
Does superoxide underlie the pathogenesis of hypertension? Proc
Natl Acad Sci U S A. 1991;88:10451048.
35.
Wei EP, Kontos HA, Christman CW, DeWitt DS, Povlishock
JT. Superoxide generation and reversal of acetylcholine-induced
cerebral arteriolar dilatation after acute hypertension. Circ
Res. 1985;57:781787.
36.
Frei B, England L, Ames BN. Ascorbate is an outstanding
antioxidant in human blood plasma. Proc Natl Acad Sci
U S A. 1989;86:63776381.
37.
Bendich A, Machlin IJ, Scandurra O, Burton GW, Wayner
DDM. The antioxidant role of vitamin C. Adv Free Radic Biol
Med. 1986;2:419444.
38.
Whitney RJ. The measurement of volume changes in human
limbs. J Physiol (Lond). 1953;121:127.
39.
Pedrinelli R, Taddei S, Graziadei L, Salvetti A.
Vascular responses to ouabain and norepinephrine in low and
normal renin hypertension. Hypertension. 1986;8:786792.
40.
Schultz KD, Schultz K, Schultz G. Sodium nitroprusside
and other smooth muscle relaxants increase cyclic GMP levels in rat
ductus deferens. Nature. 1977;265:750751.[Medline]
[Order article via Infotrieve]
41.
Ting HH, Timini TF, Boles KS, Creager SJ, Ganz P,
Creager MA. Vitamin C improves endothelium-dependent
vasodilation in patients with non-insulin-dependent diabetes mellitus.
J Clin Invest. 1996;97:2228.[Medline]
[Order article via Infotrieve]
42.
Heitzer T, Just H, Münzel T. Antioxidant vitamin
C improves endothelial dysfunction in chronic smokers.
Circulation. 1996;94:69.
43.
Garcia CE, Kilcoyne CM, Cardillo C, Cannoo RO III,
Quyyumi AA, Panza JA. Effect of copper-zinc superoxide dismutase on
endothelium-dependent vasodilation in patients with
essential hypertension. Hypertension. 1995;26(pt
1):863868.
44.
Calver A, Collier J, Moncada S, Vallance P. Effect of
local intra-arterial
NG-monomethyl-L-arginine
in patients with essential hypertension: the nitric oxide dilator
mechanism appears abnormal. J Hypertens. 1992;10:10251031.[Medline]
[Order article via Infotrieve]
45.
Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP,
Ganz P. The effect of cholesterol-lowering and antioxidant
therapy on endothelium-dependent coronary
vasomotion. N Engl J Med. 1995;332:488493.
46.
Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish RD,
Yeung AC, Vekshtein VI, Selwyn AP, Ganz P. Coronary vasomotor
response to acetylcholine relates to risk factors for coronary
artery disease. Circulation. 1990;81:491497.
47.
Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr,
Ganz P, Selwyn AP. The effect of atherosclerosis on the
vasomotor response of coronary arteries to mental stress.
N Engl J Med. 1991;325:15511556.[Abstract]
48.
Gordon JB, Ganz P, Nabel EG, Fish RD, Zebede J, Mudge
GH, Alexander RW, Selwyn AP. Atherosclerotic influences the vasomotor
response of epicardial coronary arteries to exercise.
J Clin Invest. 1989;83:19461952.
49.
Virdis A, Taddei S, Ghiadoni L, Sudano I, Di Legge V,
Meola M, Salvetti A. Endothelial function and common
carotid wall thickening in untreated essential hypertensive patients.
J Hypertens. 1996;14(suppl 1):S48. Abstract.
50.
Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney J,
Vita JA. Ascorbic acid reverses endothelial vasomotor
dysfunction in patients with coronary artery disease.
Circulation. 1996;93:11071113.
51.
Riemersma RA, Wood DA, Macintyre CCH, Elton RA, Gey KF,
Oliver MF. Low plasma vitamin E and C and increased risk of angina in
Scottish men. Ann N Y Acad Sci. 1989;570:291295.[Medline]
[Order article via Infotrieve]
52.
Stampfer MJ, Hennekens CH, Manson JE, Colditz GA,
Rosner B, Willet W. Vitamin E consumption and the risk of
coronary disease in women. N Engl J Med. 1993;328:14441449.
53.
Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E,
Colditz GA, Willet WC. Vitamin E consumption and the risk of
coronary heart disease in men. N Engl J
Med. 1993;328:14501456.
54.
Stephens NG, Parsons A, Schofield PM, Kelly F,
Cheeseman K, Mitchinson MJ, Brown MJ. Randomised controlled trial of
vitamin E in patients with coronary disease: Cambridge Heart
Antioxidant Study (CHAOS). Lancet. 1996;347:781786.[Medline]
[Order article via Infotrieve]
55.
The HOPE Study Investigators. The HOPE (Heart Outcomes
Prevention Evaluation) study: the design of a large, simple randomized
trial of an angiotensin converting enzyme
inhibitor (ramipril) and vitamin E in patients at high risk
of cardiovascular events. Can J
Cardiol. 1996;12:127137.[Medline]
[Order article via Infotrieve]
56.
Sleight P. Primary prevention of coronary heart
disease in hypertension. J Hypertens. 1996;14(suppl
2):S35S39.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Vitamin C Improves Endothelium-Dependent Vasodilation by Restoring Nitric Oxide Activity in Essential Hypertension
![]()
Abstract
Top
Abstract
Introduction
Methods
Results
Discussion
References
BackgroundEssential hypertension is
associated with impaired endothelium-dependent
vasodilation. Inactivation of endothelium-derived
nitric oxide by oxygen free radicals participates in
endothelial dysfunction in experimental hypertension.
To test this hypothesis in humans, we evaluated the effect of
antioxidant vitamin C on endothelium-dependent
responses in essential hypertensive patients.
Key Words: hypertension endothelium nitric oxide endothelium-derived factors free radicals antioxidants
![]()
Introduction
Top
Abstract
Introduction
Methods
Results
Discussion
References
Endothelium plays a
primary role in the modulation of vascular tone.1
The major endothelium-derived relaxing factor is
NO,2 a labile substance derived from
L-arginine by the activity of the enzyme NO
synthase,3 which can be specifically inhibited by
L-arginine analogues such as
L-NMMA.4 5 Moreover, endothelium
can also produce EDCFs, which are mainly
cyclooxygenase-dependent prostanoids
(TXA2 and
PGH2)6 7 8 or superoxide
anions.9
![]()
Methods
Top
Abstract
Introduction
Methods
Results
Discussion
References
Patients
The study population included 35 normotensive control subjects
and 47 matched essential hypertensive patients. Subjects with
hypercholesterolemia (total
cholesterol >240 mg/dL), diabetes mellitus, cardiac and/or
cerebral ischemic vascular disease, impaired renal function,
and other major pathologies were excluded from the study. Likewise,
subjects or patients smoking more than five cigarettes per day and/or
consuming >60 g of ethanol (corresponding to half a liter of wine) per
day were excluded from the study. In accordance with institutional
guidelines, all patients were aware of the investigational nature of
the study and gave written consent. Any pharmacological treatment was
discontinued for at least 2 weeks before the study was
performed.
.
View this table:
[in a new window]
Table 1. Characteristics of Study Subjects
All studies were performed at 8:00 AM after an
overnight fast with the subjects lying supine in a quiet,
air-conditioned room (22°C to 24°C). A polyethylene cannula (21
gauge, Abbot) was inserted into the brachial artery under local
anesthesia (2% lidocaine) and connected through stopcocks
to a pressure transducer (model MS20, Electromedics) for systemic mean
blood pressure (1/3 pulse pressure+diastolic pressure) and
heart rate monitoring (model VSM1, Physiocontrol) and for
intra-arterial infusions. FBF was measured in both forearms
(experimental and contralateral forearms) by strain-gauge venous
plethysmography (LOOSCO, GL LOOS).38 Circulation
to the hand was excluded 1 minute before each sampling or FBF
measurement by inflation of a pediatric cuff around the wrist at
suprasystolic blood pressure. Details concerning the
sensitivity and reproducibility of the method as performed in our
laboratory have already been published.39
Effect of Vitamin C on Endothelium-Dependent and
Endothelium-Independent Vasodilation
To evaluate whether oxygen free radicals can selectively impair
endothelium-dependent vasodilation in human
hypertension, in 14 essential hypertensive patients and 14 normotensive
control subjects, endothelium-dependent vasodilation
was estimated by performing a dose-response curve to
intra-arterial acetylcholine (cumulative increase in
infusion rates: 0.15, 0.45, 1.5, 4.5, 15 µg/100 mL forearm tissue per
minute, 5 minutes at each dose) while
endothelium-independent vasodilation was assessed with
a dose-response curve to intra-arterial sodium
nitroprusside, a direct smooth muscle cell relaxant
compound40 (cumulative increase: 1, 2, and 4
µg/100 mL forearm tissue per minute, 5 minutes at each dose). These
rates were selected to induce vasodilation comparable to that obtained
with acetylcholine. Both acetylcholine and sodium nitroprusside were
infused under control conditions (saline infusion at 0.2 mL/min) and in
the presence of intrabrachial vitamin C (2.4 mg/100 mL forearm tissue
per minute), which was started 10 minutes before the agonists and
continued throughout. Previous evidence has indicated that this vitamin
C infusion rate is effective in determining a local forearm
concentration shown in vitro to be capable of protecting human plasma
from free radicalmediated lipid peroxidation.36
A similar infusion rate has been used by other authors to demonstrate
that oxidative stress causes endothelial dysfunction in
type II diabetic patients41 and chronic
smokers.42 The acetylcholine or sodium
nitroprusside infusion sequence was randomized. A 30-minute washout was
allowed between each dose-response curve.
To assess whether superoxide anions can impair NO-mediated
endothelium-dependent vasodilation, in 14 normotensive
subjects and 14 essential hypertensive patients, the dose-response
curve to acetylcholine was performed according to the following design:
during saline (0.2 mL/min), in the presence of
intra-arterial L-NMMA (100 µg/100 mL forearm tissue per
minute), in the presence of intra-arterial vitamin C (2.4
mg/100 mL forearm tissue per minute), and finally in the presence of
simultaneous infusions of L-NMMA and vitamin C. Both L-NMMA
and vitamin C were started 10 minutes before acetylcholine and
continued throughout. A 30-minute washout was allowed between each
dose-response curve, and a 60-minute period was allowed when L-NMMA was
infused.
This series was designed to indirectly evaluate whether
cyclooxygenase activity could be a source of
superoxide anions in human essential hypertension. First, we performed
a dose-ranging analysis for indomethacin and
vitamin C to identify the rate at which each compound exerts its
maximal effect on the response to acetylcholine. Thus, in two
adjunctive groups of essential hypertensive patients (n=6 for each
group), the dose-response curve to acetylcholine was performed during
saline (0.2 mL/min) and repeated in the presence of increasing rates of
indomethacin (5, 15, 50, and 100 µg/100 mL forearm
tissue per minute) or vitamin C (0.8, 2.4, 8, and 16 mg/100 mL forearm
tissue per minute). After the titration study, in 7 normotensive
subjects and 7 essential hypertensive patients, the dose-response curve
to intra-arterial acetylcholine was performed during saline
(0.2 mL/min), in the presence of cyclooxygenase
inhibition by intra-arterial indomethacin
(50 µg/100 mL forearm tissue per minute started 10 minutes before
acetylcholine and continued throughout), in the presence of
intra-arterial vitamin C (2.4 mg/100 mL forearm tissue per
minute started 10 minutes before acetylcholine and continued
throughout), and finally in the presence of simultaneous
infusions of indomethacin and vitamin C. Finally, in
another 7 essential hypertension patients, the above-described
experimental design (association of indomethacin with
vitamin C) was repeated, testing the antioxidant at 8 mg/100 mL forearm
tissue per minute. A 30-minute washout was allowed between each
dose-response curve, and a 60-minute period was allowed when
indomethacin was infused.
Acetylcholine HCl (Farmigea SpA), indomethacin
(Liometacen, Chiesi Farmaceutici SpA), L-NMMA (Clinalfa AG), vitamin C
(Bracco), and sodium nitroprusside (Malesci) were obtained from
commercially available sources and diluted freshly to the desired
concentration by the addition of normal saline. Sodium nitroprusside
was dissolved in glucose solution and protected from light by
aluminum foil.
Because arterial pressure did not change
significantly during the study, all data were analyzed in terms
of FBF. FBF increments were taken as evidence of local vasodilation.
Clinical characteristics of study subjects shown in the Table
were
compared by unpaired Student's t test. Responses to
acetylcholine and sodium nitroprusside were analyzed by ANOVA
for repeated measures, and Scheffé's test was applied for
multiple comparison testing. Results are expressed as mean±SD.
![]()
Results
Top
Abstract
Introduction
Methods
Results
Discussion
References
Effect of Vitamin C on Endothelium-Dependent and
Endothelium-Independent Vasodilation
Vasodilation to acetylcholine was significantly
(P<0.01) blunted in essential hypertensive patients (FBF
rose from 3.6±0.5 to a maximum of 16.5±2.7 mL/100 mL forearm tissue
per minute with the highest dose) compared with normotensive control
subjects (FBF rose from 3.6±0.6 to a maximum of 22.8±3.3 mL/100 mL
forearm tissue per minute with the highest dose) (Figure 1
). In contrast, the vasodilating effect
of sodium nitroprusside was similar in normotensive subjects and
essential hypertensive patients (FBF rose from 3.5±0.4 to a maximum of
18.9±3.2 mL/100 mL forearm tissue per minute with the highest dose and
from 3.4±0.4 to a maximum of 180.0±30.0 mL/100 mL forearm tissue per
minute, respectively; P=NS) (Figure 1
). Vitamin C
administration did not change basal FBF in either normotensive or
hypertensive subjects. However, whereas in healthy control subjects the
free radical scavenger did not change the response to acetylcholine
(FBF rose from 3.5±0.6 to a maximum of 22.0±3.1 mL/100 mL forearm
tissue per minute with the highest dose) (Figure 1
), in essential
hypertensive patients vitamin C significantly increased the
vasodilating effect of the muscarinic agonist (FBF rose from 3.5±0.6
to a maximum of 20.8±2.6 mL/100 mL forearm tissue per minute with the
highest dose) (Figure 1
). In contrast, the response to sodium
nitroprusside was not affected by vitamin C in normotensive subjects
and essential hypertensive patients (FBF rose from 3.5±0.6 to a
maximum of 18.1±3.3 mL/100 mL forearm tissue per minute with the
highest dose and from 3.6±0.5 to a maximum of 19.1±2.4 mL/100 mL
forearm tissue per minute, respectively; P=NS) (Figure 1
).
In both normotensive subjects and essential hypertensive patients,
contralateral FBF did not significantly change throughout the study
(data not shown).

View larger version (17K):
[in a new window]
Figure 1. FBF increase above basal (b) induced by
intra-arterial acetylcholine (left) and sodium
nitroprusside (SNP; right) in the absence (saline at 0.2 mL/min) (
)
and presence (
) of vitamin C (2.4 mg/100 mL forearm
tissue per minute) in normotensive subjects (n=14; top) and essential
hypertensive patients (n=14; bottom). Data are shown as mean±SD and
expressed as absolute values. *Significant difference between the
response to acetylcholine in the absence and presence of vitamin C
(P<0.05).
In normotensive subjects, L-NMMA infusion, which caused a decrease
in basal FBF (from 3.6±0.4 to 2.2±0.2 mL/100 mL forearm tissue per
minute; P<0.01), significantly blunted the vasodilating
effect of acetylcholine (saline, from 3.6±0.5 to 22.7±3.7 mL/100 mL
forearm tissue per minute; L-NMMA, from 2.2±0.2 to 9.9±1.8 mL/100 mL
forearm tissue per minute; P<0.01 versus acetylcholine
alone) (Figure 2
). Vitamin C did not
change either the response to acetylcholine (from 3.7±0.5 to 23.1±3.2
mL/100 mL forearm tissue per minute) or the inhibiting effect of L-NMMA
on vasodilation to acetylcholine (from 2.2±10.0 to 10.9±2.1 mL/100 mL
forearm tissue per minute) (Figure 2
). In contrast, in essential
hypertensive patients, L-NMMA infusion, which caused a smaller decrease
in basal FBF (from 3.5±0.5 to 2.6±0.2 mL/100 mL forearm tissue per
minute; P<0.01) compared with normotensive control subjects
(percent FBF decrease, 39% versus 25%, respectively;
P<0.01), did not change the response to acetylcholine
(saline, from 3.6±0.5 to 16.7±2.3 mL/100 mL forearm tissue per
minute; L-NMMA, from 2.6±0.2 to 9.9±1.9 mL/100 mL forearm tissue per
minute; P=NS versus saline) (Figure 2
). Vitamin C infusion
increased the response to acetylcholine (from 3.6±0.4 to 21.1±2.6
mL/100 mL forearm tissue per minute; P<0.01 versus
acetylcholine during saline) (Figure 2
). When the effect of L-NMMA was
retested in the presence of vitamin C, the NO-synthase
inhibitor blunted the vasodilating effect of acetylcholine
(from 2.6±0.2 to 11.4±1.8 mL/100 mL forearm tissue per minute;
P<0.01 versus acetylcholine in the presence of vitamin C
alone) (Figure 2
). In both normotensive subjects and essential
hypertensive patients, contralateral FBF did not significantly change
throughout the study (data not shown).

View larger version (21K):
[in a new window]
Figure 2. Acetylcholine-induced increase in FBF in the
absence (left) and presence (right) of vitamin C (2.4 mg/100 mL forearm
tissue per minute) under control conditions (saline at 0.2 mL/min) and
in the presence of L-NMMA (100 µg/100 mL forearm tissue per minute)
in normotensive subjects (n=14; top) and essential hypertensive
patients (n=14; bottom). Data are shown as mean±SD and, because L-NMMA
modifies basal FBF, are expressed as percent increase above basal.
*Significant difference between infusion with and without L-NMMA
(P<0.05).
The preliminary titration study showed that acetylcholine-induced
vasodilation (from 30.0±0.5 to 15.1±2.1 mL/100 mL forearm tissue per
minute) was increased by indomethacin in a
dose-dependent manner (Figure 3
). The
cyclooxygenase inhibitor reached its
maximum effect at the infusion rate of 50 µg/100 mL forearm tissue
per minute (from 3.3±0.4 to 25.7±2.9 mL/100 mL forearm tissue per
minute; P<0.001 versus saline), with no further increase at
the greatest concentration of 100 µg/100 mL forearm tissue per minute
(from 3.4±0.4 to 26.9±2.8 mL/100 mL forearm tissue per minute;
P<0.001 versus saline and P=NS versus
indomethacin at 50 µg/100 mL forearm tissue per
minute) (Figure 3
). Vitamin C also dose dependently increased the
response to acetylcholine (from 30.0±0.2 to 16.2±2.1 mL/100 mL
forearm tissue per minute), with a maximum effect obtained with the
infusion rate of 8 mg/100 mL forearm tissue per minute (from 3.1±0.5
to 27.5±3.1 mL/100 mL forearm tissue per minute; P<0.001
versus saline) (Figure 3
) and no further increase obtained with 16
mg/100 mL forearm tissue per minute (from 3.2±0.5 to 28.7±3.6 mL/100
mL forearm tissue per minute; P<0.001 versus saline and
P=NS versus vitamin C at 8 mg/100 mL forearm tissue per
minute) (Figure 3
).

View larger version (28K):
[in a new window]
Figure 3. Acetylcholine-induced increase in FBF in the
presence of saline (0.2 mL/min) (+) or vitamin C at 0.8 (
), 2.4
(
), 8 (
), and 16 (
) mg/100 mL forearm tissue per
minute and in the presence of saline (+) or
indomethacin at 5 (
), 15 (
), 50 (
) and 100
(
) µg/100 mL forearm tissue per minute in two distinct groups of
essential hypertensive patients (n=6 each). Data are shown as mean±SD
and expressed as absolute values. *Significant difference between
infusion under control conditions and in the presence of different
infusion rates of indomethacin or vitamin C
(P<0.05).
).
In essential hypertensive patients, acetylcholine infusion caused a
dose-dependent vasodilation (from 3.7±0.5 to 17.9±2.3 mL/100 mL
forearm tissue per minute) that was significantly increased both by
indomethacin (50 µg/100 mL forearm tissue per minute)
(from 3.5±0.4 to 24.3±3.1 mL/100 mL forearm tissue per minute;
P<0.01 versus acetylcholine alone) and vitamin C (2.4
mg/100 mL forearm tissue per minute) (from 3.6±0.5 to 20.3±2.4 mL/100
mL forearm tissue per minute; P<0.05 versus acetylcholine
alone). Indomethacin-induced increase in vasodilation
to acetylcholine was greater than the potentiation exerted by vitamin C
(percent increase above basal of maximum to acetylcholine: during
saline, 392.6±45.3%; during indomethacin,
595.8±67.4% [P<0.001 versus saline]; during vitamin C,
468.8±55.3% [P<0.01 versus saline and P<0.05
versus indomethacin]). When
indomethacin was coinfused with vitamin C, these
compounds did not exert an additive effect compared with that exerted
by indomethacin alone (from 3.7±0.4 to 23.7±3.1
mL/100 mL forearm tissue per minute; P<0.01 versus
acetylcholine during saline) (percent increase above basal of maximum
to acetylcholine, 540.4±67.2; P=NS versus
indomethacin). However, in the final group of
hypertensive patients, vitamin C at the higher infusion rate of 8
mg/100 mL forearm tissue per minute significantly increased the
response to acetylcholine (saline, from 3.5±0.5 to 16.5±2.4 mL/100 mL
forearm tissue per minute; vitamin C, from 3.6±0.6 to 23.6±3.2 mL/100
mL forearm tissue per minute; P<0.01 versus acetylcholine
alone), and this effect was no longer different from that exerted by
indomethacin (50 µg/100 mL forearm tissue per minute)
(from 3.5±0.5 to 22.5±30.0 mL/100 mL forearm tissue per minute;
P<0.01 versus acetylcholine alone). Again, when
indomethacin and vitamin C were coinfused, the
potentiating effect of the combined compounds was similar to that
observed with each one infused alone (from 3.7±0.5 to 24.1±3.2 mL/100
mL forearm tissue per minute; P<0.01 versus acetylcholine
during saline) (Figure 4
). In both normotensive subjects and
hypertensive patients, contralateral FBF did not change significantly
(data not shown).

View larger version (20K):
[in a new window]
Figure 4. Acetylcholine-induced increase in FBF in the
presence of saline (0.2 mL/min) (
); indomethacin (50
µg/100 mL forearm tissue per minute) (
); vitamin C (8 mg/100 mL
forearm tissue per minute) (O); and simultaneous
indomethacin and vitamin C (
) in normotensive
subjects (n=7) and essential hypertensive patients (n=7). Data are
shown as mean±SD and expressed as absolute values. *Significant
difference between infusion under control conditions and in the
presence of vitamin C, indomethacin, or vitamin C plus
indomethacin (P<0.05).
![]()
Discussion
Top
Abstract
Introduction
Methods
Results
Discussion
References
In the present investigation, we tested the hypothesis that
increased NO breakdown by oxygen free radicals accounts for the
impaired endothelium-dependent vasodilation in patients
with essential hypertension. In agreement with previous
observations,10 11 12 13 14 15 16 17 18 the response to acetylcholine
but not to sodium nitroprusside was found to be reduced in essential
hypertensive patients compared with normotensive control subjects,
confirming the presence of endothelial dysfunction in
essential hypertension. However, the impaired
endothelium-dependent vasodilation was markedly
improved by vitamin C in essential hypertensive patients. This effect
of the superoxide anion scavenger was specific, because it was observed
neither in healthy control subjects nor on
endothelium-independent vasodilation induced by sodium
nitroprusside. Taken together, these findings indicate that antioxidant
vitamin C improves endothelial function in essential
hypertensive patients, probably by directly scavenging oxygen free
radicals within the vasculature, and strongly suggest that superoxide
anion production is a likely candidate to account for
endothelial dysfunction in essential hypertension.
![]()
Selected Abbreviations and Acronyms
EDCF
=
endothelium-derived contracting factor
FBF
=
forearm blood flow
L-NMMA
=
NG-monomethyl-L-arginine
NO
=
nitric oxide
PGH2
=
prostaglandin H2
SOD
=
superoxide dismutase
TXA2
=
thromboxane A2
![]()
References
Top
Abstract
Introduction
Methods
Results
Discussion
References
1.
Lüscher TF, Vanhoutte PM. The
Endothelium: Modulator of
Cardiovascular Function. Boca Raton, Fla: CRC
Press; 1990:1215.
This article has been cited by other articles:
![]() |
C. Giannarelli, A. Virdis, F. De Negri, A. Magagna, E. Duranti, A. Salvetti, and S. Taddei Effect of Sulfaphenazole on Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients Circulation, March 31, 2009; 119(12): 1625 - 1633. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Versari, E. Daghini, A. Virdis, L. Ghiadoni, and S. Taddei The ageing endothelium, cardiovascular risk and disease in man Exp Physiol, March 1, 2009; 94(3): 317 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Momen, V. Mascarenhas, A. Gahremanpour, Z. Gao, R. Moradkhan, A. Kunselman, J. P. Boehmer, L. I. Sinoway, and U. A. Leuenberger Coronary blood flow responses to physiological stress in humans Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H854 - H861. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Lesniewski, M. L. Connell, J. R. Durrant, B. J. Folian, M. C. Anderson, A. J. Donato, and D. R. Seals B6D2F1 Mice Are a Suitable Model of Oxidative Stress-Mediated Impaired Endothelium-Dependent Dilation With Aging J Gerontol A Biol Sci Med Sci, February 10, 2009; (2009) gln049v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Churchill, M.-H. Disatnik, G. R. Budas, and D. Mochly-Rosen Ethanol for cardiac ischemia: the role of protein kinase c Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 469 - 483. [Abstract] [PDF] |
||||
![]() |
L. G. Sanchez-Lozada, V. Soto, E. Tapia, C. Avila-Casado, Y. Y. Sautin, T. Nakagawa, M. Franco, B. Rodriguez-Iturbe, and R. J. Johnson Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1134 - F1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway Hypertension, August 1, 2008; 52(2): 314 - 321. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Van Guilder, G. L. Hoetzer, J. J. Greiner, B. L. Stauffer, and C. A. DeSouza Acute and chronic effects of vitamin C on endothelial fibrinolytic function in overweight and obese adult humans J. Physiol., July 15, 2008; 586(14): 3525 - 3535. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Holowatz, C. S. Thompson-Torgerson, and W. L. Kenney The human cutaneous circulation as a model of generalized microvascular function J Appl Physiol, July 1, 2008; 105(1): 370 - 372. [Full Text] [PDF] |
||||
![]() |
A. Ceriello Possible Role of Oxidative Stress in the Pathogenesis of Hypertension Diabetes Care, February 1, 2008; 31(Supplement_2): S181 - S184. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Gkaliagkousi, J. Ritter, and A. Ferro Platelet-Derived Nitric Oxide Signaling and Regulation Circ. Res., September 28, 2007; 101(7): 654 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Holowatz and W. L. Kenney Local ascorbate administration augments NO- and non-NO-dependent reflex cutaneous vasodilation in hypertensive humans Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1090 - H1096. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Holowatz and W. L. Kenney Up-regulation of arginase activity contributes to attenuated reflex cutaneous vasodilatation in hypertensive humans J. Physiol., June 1, 2007; 581(2): 863 - 872. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Giannarelli, F. De Negri, A. Virdis, L. Ghiadoni, A. Cipriano, A. Magagna, S. Taddei, and A. Salvetti Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients Hypertension, April 1, 2007; 49(4): 878 - 884. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Schrage, J. H. Eisenach, and M. J. Joyner Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans J. Physiol., February 15, 2007; 579(1): 227 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. George, E. Carr, J. Davies, J.J.F. Belch, and A. Struthers High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid Circulation, December 5, 2006; 114(23): 2508 - 2516. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dardano, L. Ghiadoni, Y. Plantinga, N. Caraccio, A. Bemi, E. Duranti, S. Taddei, E. Ferrannini, A. Salvetti, and F. Monzani Recombinant Human Thyrotropin Reduces Endothelium-Dependent Vasodilation in Patients Monitored for Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4175 - 4178. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Feletou and P. M. Vanhoutte Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture) Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H985 - H1002. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, D. Versari, A. Cipriano, L. Ghiadoni, F. Galetta, F. Franzoni, A. Magagna, A. Virdis, and A. Salvetti Identification of a Cytochrome P450 2C9-Derived Endothelium-Derived Hyperpolarizing Factor in Essential Hypertensive Patients J. Am. Coll. Cardiol., August 1, 2006; 48(3): 508 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bernini, D. Versari, A. Moretti, A. Virdis, L. Ghiadoni, M. Bardini, C. Taurino, D. Canale, S. Taddei, and A. Salvetti Vascular Reactivity in Congenital Hypogonadal Men before and after Testosterone Replacement Therapy J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1691 - 1697. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Grebe, H. J. Eisele, N. Weissmann, C. Schaefer, H. Tillmanns, W. Seeger, and R. Schulz Antioxidant Vitamin C Improves Endothelial Function in Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 897 - 901. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Bell and K. Gochenaur Direct vasoactive and vasoprotective properties of anthocyanin-rich extracts J Appl Physiol, April 1, 2006; 100(4): 1164 - 1170. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Chen, R. J. Karne, G. Hall, U. Campia, J. A. Panza, R. O. Cannon III, Y. Wang, A. Katz, M. Levine, and M. J. Quon High-dose oral vitamin C partially replenishes vitamin C levels in patients with Type 2 diabetes and low vitamin C levels but does not improve endothelial dysfunction or insulin resistance Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H137 - H145. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Brzezinska, N. Lohr, and W. M. Chilian Electrophysiological effects of O2-{middle dot} on the plasma membrane in vascular endothelial cells Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2379 - H2386. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Z. Sheng, D. Wang, and A. P. Braun DAF-FM (4-Amino-5-methylamino-2',7'-difluorofluorescein) Diacetate Detects Impairment of Agonist-Stimulated Nitric Oxide Synthesis by Elevated Glucose in Human Vascular Endothelial Cells: Reversal by Vitamin C and L-Sepiapterin J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 931 - 940. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Drenjancevic-Peric, S. A. Phillips, J. R. Falck, and J. H. Lombard Restoration of normal vascular relaxation mechanisms in cerebral arteries by chromosomal substitution in consomic SS.13BN rats Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H188 - H195. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. O. Lundberg and E. Weitzberg NO Generation From Nitrite and Its Role in Vascular Control Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 915 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Delles, M. P. Schneider, S. Oehmer, I. Fleischmann, E. F. Fleischmann, and R. E. Schmieder Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes Nephrol. Dial. Transplant., October 1, 2004; 19(10): 2513 - 2518. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Sim, C. Farquharson, and A. D Struthers Tonic levels of angiotensin II reduce tonic levels of vascular nitric oxide even in salt-replete man Journal of Renin-Angiotensin-Aldosterone System, June 1, 2004; 5(2): 84 - 88. [Abstract] [PDF] |
||||
![]() |
F Violi, L Loffredo, L Musella, and A Marcoccia Should antioxidant status be considered in interventional trials with antioxidants? Heart, June 1, 2004; 90(6): 598 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kawashima and M. Yokoyama Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 998 - 1005. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cipollone, E. Toniato, S. Martinotti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, S. Ursi, G. Vitullo, M. Averna, et al. A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke JAMA, May 12, 2004; 291(18): 2221 - 2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rodriguez-Iturbe, N. D. Vaziri, J. Herrera-Acosta, and R. J. Johnson Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all Am J Physiol Renal Physiol, April 1, 2004; 286(4): F606 - F616. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Eskurza, K. D. Monahan, J. A. Robinson, and D. R. Seals Ascorbic acid does not affect large elastic artery compliance or central blood pressure in young and older men Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1528 - H1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Simon, M. A. Murtaugh, M. D. Gross, C. M. Loria, S. B. Hulley, and D. R. Jacobs Jr. Relation of Ascorbic Acid to Coronary Artery Calcium: The Coronary Artery Risk Development in Young Adults Study Am. J. Epidemiol., March 15, 2004; 159(6): 581 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Karanth, W. H. Yu, C. A Mastronardi, and S. M. McCann Inhibition of Stimulated Ascorbic Acid and Luteinizing Hormone-Releasing Hormone Release by Nitric Oxide Synthase or Guanyl Cyclase Inhibitors Experimental Biology and Medicine, January 1, 2004; 229(1): 72 - 79. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Minuz, P. Patrignani, S. Gaino, F. Seta, M. L. Capone, S. Tacconelli, M. Degan, G. Faccini, A. Fornasiero, G. Talamini, et al. Determinants of Platelet Activation in Human Essential Hypertension Hypertension, January 1, 2004; 43(1): 64 - 70. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kinugawa, H. Post, P. M. Kaminski, X. Zhang, X. Xu, H. Huang, F. A. Recchia, M. Ochoa, M. S. Wolin, G. Kaley, et al. Coronary Microvascular Endothelial Stunning After Acute Pressure Overload in the Conscious Dog Is Caused by Oxidant Processes: The Role of Angiotensin II Type 1 Receptor and NAD(P)H Oxidase Circulation, December 9, 2003; 108(23): 2934 - 2940. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cominacini, A. Fratta Pasini, U. Garbin, C. Nava, A. Davoli, M. Criscuoli, A. Crea, T. Sawamura, and V. Lo Cascio Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation J. Am. Coll. Cardiol., November 19, 2003; 42(10): 1838 - 1844. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hermann, G. Camici, A. Fratton, D. Hurlimann, F. C. Tanner, J. P. Hellermann, M. Fiedler, J. Thiery, M. Neidhart, R. E. Gay, et al. Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Endothelial Function in Salt-Induced Hypertension Circulation, November 11, 2003; 108(19): 2308 - 2311. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Zhou, A. G. Adam, E. A. Jaimes, and L. Raij In Salt-Sensitive Hypertension, Increased Superoxide Production Is Linked to Functional Upregulation of Angiotensin II Hypertension, November 1, 2003; 42(5): 945 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H. Schindler, E. U. Nitzsche, T. Munzel, M. Olschewski, I. Brink, M. Jeserich, M. Mix, P. T. Buser, M. Pfisterer, U. Solzbach, et al. Coronary vasoregulation in patients with various risk factors in response to cold pressor testing: Contrasting myocardial blood flow responses to short- and long-term vitamin C administration J. Am. Coll. Cardiol., September 3, 2003; 42(5): 814 - 822. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. K Heilbronn and E. Ravussin Calorie restriction and aging: review of the literature and implications for studies in humans Am. J. Clinical Nutrition, September 1, 2003; 78(3): 361 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Widlansky, D. T. Price, N. Gokce, R. T. Eberhardt, S. J. Duffy, M. Holbrook, C. Maxwell, J. Palmisano, J. F. Keaney Jr, J. D. Morrow, et al. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension Hypertension, September 1, 2003; 42(3): 310 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Laemmel, E. Bonnardel-Phu, X. Hou, J. Seror, and E. Vicaut Interaction between nitric oxide and prostanoids in arterioles of rat cremaster muscle in vivo Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1254 - H1260. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, N. Caraccio, A. Virdis, A. Dardano, D. Versari, L. Ghiadoni, A. Salvetti, E. Ferrannini, and F. Monzani Impaired Endothelium-Dependent Vasodilatation in Subclinical Hypothyroidism: Beneficial Effect of Levothyroxine Therapy J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3731 - 3737. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ghiadoni, A. Magagna, D. Versari, I. Kardasz, Y. Huang, S. Taddei, and A. Salvetti Different Effect of Antihypertensive Drugs on Conduit Artery Endothelial Function Hypertension, June 1, 2003; 41(6): 1281 - 1286. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Piccirillo, M. Nocco, A. Moise, M. Lionetti, C. Naso, S. di Carlo, and V. Marigliano Influence of Vitamin C on Baroreflex Sensitivity in Chronic Heart Failure Hypertension, June 1, 2003; 41(6): 1240 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mollnau, E. Schulz, A. Daiber, S. Baldus, M. Oelze, M. August, M. Wendt, U. Walter, C. Geiger, R. Agrawal, et al. Nebivolol Prevents Vascular NOS III Uncoupling in Experimental Hyperlipidemia and Inhibits NADPH Oxidase Activity in Inflammatory Cells Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 615 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, A. Virdis, L. Ghiadoni, D. Versari, G. Salvetti, A. Magagna, and A. Salvetti Calcium Antagonist Treatment by Lercanidipine Prevents Hyperpolarization in Essential Hypertension Hypertension, April 1, 2003; 41(4): 950 - 955. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ulker, P. P. McKeown, and U. Bayraktutan Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities Hypertension, March 1, 2003; 41(3): 534 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. V. d'Uscio, S. Milstien, D. Richardson, L. Smith, and Z. S. Katusic Long-Term Vitamin C Treatment Increases Vascular Tetrahydrobiopterin Levels and Nitric Oxide Synthase Activity Circ. Res., January 10, 2003; 92(1): 88 - 95. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, K. Nakagawa, M. Kimura, K. Noma, K. Hara, S. Sasaki, C. Goto, T. Oshima, K. Chayama, and M. Yoshizumi Circadian variation of blood pressure and endothelial function in patients with essential hypertension: a comparison of dippers and non-dippers J. Am. Coll. Cardiol., December 4, 2002; 40(11): 2039 - 2043. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Bell, K. E. Gochenaur, and J. Hecht O2--mediated impairment of coronary arterial relaxation is prevented by overnight treatment with 1 nM beta -estradiol J Appl Physiol, December 1, 2002; 93(6): 1952 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Singh, J. Graves, P. D Taylor, R. J MacAllister, and D. R.J Singer Effects of a 'healthy' diet and of acute and long-term vitamin C on vascular function in healthy older subjects Cardiovasc Res, October 1, 2002; 56(1): 118 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meng, L. J. Roberts II, G. W. Cason, T. S. Curry, and R. D. Manning Jr. Superoxide dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2002; 283(3): R732 - R738. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xu, G. D. Fink, and J. J. Galligan Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in DOCA-salt rats Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H885 - H892. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Kahn, S. J. Duffy, D. Tomasian, M. Holbrook, L. Rescorl, J. Russell, N. Gokce, J. Loscalzo, and J. A. Vita Effects of Black Race on Forearm Resistance Vessel Function Hypertension, August 1, 2002; 40(2): 195 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, T. Oshima, and K. Chayama Endothelial Function and Oxidative Stress in Renovascular Hypertension N. Engl. J. Med., June 20, 2002; 346(25): 1954 - 1962. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Govers, P. van der Sluijs, E. van Donselaar, J.-W. Slot, and T. J. Rabelink Endothelial Nitric Oxide Synthase and Its Negative Regulator Caveolin-1 Localize to Distinct Perinuclear Organelles J. Histochem. Cytochem., June 1, 2002; 50(6): 779 - 788. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cardillo, U. Campia, C. M. Kilcoyne, M. B. Bryant, and J. A. Panza Improved Endothelium-Dependent Vasodilation After Blockade of Endothelin Receptors in Patients With Essential Hypertension Circulation, January 29, 2002; 105(4): 452 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Aizawa, N. Ishizaka, S.-I. Usui, N. Ohashi, M. Ohno, and R. Nagai Angiotensin II and Catecholamines Increase Plasma Levels of 8-Epi-Prostaglandin F2{alpha} With Different Pressor Dependencies in Rats Hypertension, January 1, 2002; 39(1): 149 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. MacCarthy, D. J. Grieve, J.-M. Li, C. Dunster, F. J. Kelly, and A. M. Shah Impaired Endothelial Regulation of Ventricular Relaxation in Cardiac Hypertrophy: Role of Reactive Oxygen Species and NADPH Oxidase Circulation, December 11, 2001; 104(24): 2967 - 2974. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zalba, G. S. Jose, M. U. Moreno, M. A. Fortuno, A. Fortuno, F. J. Beaumont, and J. Diez Oxidative Stress in Arterial Hypertension: Role of NAD(P)H Oxidase Hypertension, December 1, 2001; 38(6): 1395 - 1399. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Davidge Prostaglandin H Synthase and Vascular Function Circ. Res., October 12, 2001; 89(8): 650 - 660. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Imamura, S. Biro, T. Kihara, S. Yoshifuku, K. Takasaki, Y. Otsuji, S. Minagoe, Y. Toyama, and C. Tei Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1083 - 1088. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Virdis, L. Ghiadoni, H. Cardinal, S. Favilla, P. Duranti, R. Birindelli, A. Magagna, G. Bernini, G. Salvetti, S. Taddei, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1106 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
D C Chambers and J G Ayres Effects of nitrogen dioxide exposure and ascorbic acid supplementation on exhaled nitric oxide in healthy human subjects Thorax, October 1, 2001; 56(10): 774 - 778. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P. Bell, S. I. Mosfer, D. Lang, F. Donaldson, and M. J. Lewis Vitamin C and quinapril abrogate LVH and endothelial dysfunction in aortic-banded guinea pigs Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1704 - H1710. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen, R. M. Touyz, J. B. Park, and E. L. Schiffrin Antioxidant Effects of Vitamins C and E Are Associated With Altered Activation of Vascular NADPH Oxidase and Superoxide Dismutase in Stroke-Prone SHR Hypertension, September 1, 2001; 38(3): 606 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, A. Virdis, L. Ghiadoni, G. Salvetti, G. Bernini, A. Magagna, and A. Salvetti Age-Related Reduction of NO Availability and Oxidative Stress in Humans Hypertension, August 1, 2001; 38(2): 274 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perticone, R. Ceravolo, A. Pujia, G. Ventura, S. Iacopino, A. Scozzafava, A. Ferraro, M. Chello, P. Mastroroberto, P. Verdecchia, et al. Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients Circulation, July 10, 2001; 104(2): 191 - 196. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. A. Witte, A. L. Clark, and J. G. F. Cleland Chronic heart failure and micronutrients J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1765 - 1774. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Simon, E. S. Hudes, and J. A. Tice Relation of Serum Ascorbic Acid to Mortality Among US Adults J. Am. Coll. Nutr., June 1, 2001; 20(3): 255 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Rizzoni, E. Porteri, D. Guelfi, M. L. Muiesan, U. Valentini, A. Cimino, A. Girelli, L. Rodella, R. Bianchi, I. Sleiman, et al. Structural Alterations in Subcutaneous Small Arteries of Normotensive and Hypertensive Patients With Non-Insulin-Dependent Diabetes Mellitus Circulation, March 6, 2001; 103(9): 1238 - 1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, S. Sasaki, K. Nakagawa, H. Matsuura, G. Kajiyama, and T. Oshima Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function J. Am. Coll. Cardiol., March 1, 2001; 37(3): 863 - 870. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, A. Virdis, L. Ghiadoni, A. Magagna, S. Favilla, A. Pompella, and A. Salvetti Restoration of Nitric Oxide Availability After Calcium Antagonist Treatment in Essential Hypertension Hypertension, March 1, 2001; 37(3): 943 - 948. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Grossmann, D. Dobrev, H. M. Himmel, U. Ravens, and W. Kirch Ascorbic Acid-Induced Modulation of Venous Tone in Humans Hypertension, March 1, 2001; 37(3): 949 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Duffy, N. Gokce, M. Holbrook, L. M. Hunter, E. S. Biegelsen, A. Huang, J. F. Keaney Jr., and J. A. Vita Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H528 - H534. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Rossi, S. Taddei, A. Virdis, L. Ghiadoni, G. Albertin, S. Favilla, I. Sudano, A. C. Pessina, and A. Salvetti Exclusion of the ACE D/I Gene Polymorphism as a Determinant of Endothelial Dysfunction Hypertension, February 1, 2001; 37(2): 293 - 300. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perticone, R. Ceravolo, M. Candigliota, G. Ventura, S. Iacopino, F. Sinopoli, and P. L. Mattioli Obesity and Body Fat Distribution Induce Endothelial Dysfunction by Oxidative Stress: Protective Effect of Vitamin C Diabetes, January 1, 2001; 50(1): 159 - 165. [Abstract] [Full Text] |
||||
![]() |
O. A. Paniagua, M. B. Bryant, and J. A. Panza Transient Hypertension Directly Impairs Endothelium-Dependent Vasodilation of the Human Microvasculature Hypertension, December 1, 2000; 36(6): 941 - 944. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ghiadoni, A. E. Donald, M. Cropley, M. J. Mullen, G. Oakley, M. Taylor, G. O'Connor, J. Betteridge, N. Klein, A. Steptoe, et al. Mental Stress Induces Transient Endothelial Dysfunction in Humans Circulation, November 14, 2000; 102(20): 2473 - 2478. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Natali, A. M. Sironi, E. Toschi, S. Camastra, G. Sanna, A. Perissinotto, S. Taddei, and E. Ferrannini Effect of Vitamin C on Forearm Blood Flow and Glucose Metabolism in Essential Hypertension Arterioscler. Thromb. Vasc. Biol., November 1, 2000; 20(11): 2401 - 2406. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. E. Rush, M. H. Laughlin, C. R. Woodman, and E. M. Price SOD-1 expression in pig coronary arterioles is increased by exercise training Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2068 - H2076. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Rankinen, T. Rice, L. Perusse, Y. C. Chagnon, J. Gagnon, A. S. Leon, J. S. Skinner, J. H. Wilmore, D. C. Rao, and C. Bouchard NOS3 Glu298Asp Genotype and Blood Pressure Response to Endurance Training : The HERITAGE Family Study Hypertension, November 1, 2000; 36(5): 885 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kaufmann, T. Gnecchi-Ruscone, M. di Terlizzi, K. P. Schafers, T. F. Luscher, and P. G. Camici Coronary Heart Disease in Smokers : Vitamin C Restores Coronary Microcirculatory Function Circulation, September 12, 2000; 102(11): 1233 - 1238. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Oomen, M. J. van Erk, E. J. M. Feskens, F. J. Kok, and D. Kromhout Arginine Intake and Risk of Coronary Heart Disease Mortality in Elderly Men Arterioscler. Thromb. Vasc. Biol., September 1, 2000; 20(9): 2134 - 2139. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tomasian, J. F. Keaney Jr., and J. A. Vita Antioxidants and the bioactivity of endothelium-derived nitric oxide Cardiovasc Res, August 18, 2000; 47(3): 426 - 435. [Full Text] [PDF] |
||||
![]() |
A. Schrammel, D. Koesling, K. Schmidt, and B. Mayer Inhibition of purified soluble guanylyl cyclase by L-ascorbic acid Cardiovasc Res, August 18, 2000; 47(3): 602 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lembo, C. Vecchione, R. Izzo, L. Fratta, D. Fontana, G. Marino, G. Pilato, and B. Trimarco Noradrenergic Vascular Hyper-Responsiveness in Human Hypertension Is Dependent on Oxygen Free Radical Impairment of Nitric Oxide Activity Circulation, August 1, 2000; 102(5): 552 - 557. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Taddei, F. Galetta, A. Virdis, L. Ghiadoni, G. Salvetti, F. Franzoni, C. Giusti, and A. Salvetti Physical Activity Prevents Age-Related Impairment in Nitric Oxide Availability in Elderly Athletes Circulation, June 27, 2000; 101(25): 2896 - 2901. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Virdis, L. Ghiadoni, S. Pinto, M. Lombardo, F. Petraglia, A. Gennazzani, S. Buralli, S. Taddei, and A. Salvetti Mechanisms Responsible for Endothelial Dysfunction Associated With Acute Estrogen Deprivation in Normotensive Women Circulation, May 16, 2000; 101(19): 2258 - 2263. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. T. Raitakari, M. R. Adams, R. J. McCredie, K. A. Griffiths, R. Stocker, and D. S. Celermajer Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1616 - 1621. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Sherman, J. F. Keaney Jr, E. S. Biegelsen, S. J. Duffy, J. D. Coffman, and J. A. Vita Pharmacological Concentrations of Ascorbic Acid Are Required for the Beneficial Effect on Endothelial Vasomotor Function in Hypertension Hypertension, April 1, 2000; 35(4): 936 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Stefanec Endothelial Apoptosis: Could It Have a Role in the Pathogenesis and Treatment of Disease? Chest, March 1, 2000; 117(3): 841 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Fujiwara, T. Osanai, T. Kamada, T. Katoh, K. Takahashi, and K. Okumura Study on the Relationship Between Plasma Nitrite and Nitrate Level and Salt Sensitivity in Human Hypertension : Modulation of Nitric Oxide Synthesis by Salt Intake Circulation, February 29, 2000; 101(8): 856 - 861. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |